Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Thiele

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Antioxidants & Redox Signaling|August 24, 2005
Link between macrophage migration inhibitory factor and cellular redox regulationMichael Thiele, Jürgen Bernhagen
Methods in Molecular Biology (Clifton, N.J.)|May 13, 2026
Detection of Oxidized Macrophage Migration Inhibitory Factor (oxMIF) in Biological Samples Using Enzyme-Linked Immunosorbent Assay (ELISA)Gregor Rossmueller, Michael Thiele
Current Hematology Reports|May 4, 2005
Diagnosis of polycythemia vera based on bone marrow pathologyJuergen Michael Thiele, Hans Michael Kvasnicka
Journal for Immunotherapy of Cancer|September 30, 2022
OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseasesMichael Thiele, Seamas C Donnelly, Robert A Mitchell
Antibodies (Basel, Switzerland)|December 27, 2024
Integrating In Silico and In Vitro Tools for Optimized Antibody Development-Design of Therapeutic Anti-oxMIF AntibodiesGregor Rossmueller, Irina Mirkina, Michael Thiele, et al.
Circulation|December 24, 2003
Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient miceAndreas Schober, Jürgen Bernhagen, Michael Thiele, et al.
FEBS Letters|March 11, 2005
Binding of JAB1/CSN5 to MIF is mediated by the MPN domain but is independent of the JAMM motifAnke Burger-Kentischer, Doris Finkelmeier, Michael Thiele, et al.
Molecular Cancer Therapeutics|June 4, 2024
Pretargeted radioimmunotherapy with the novel anti-oxMIF/HSG bispecific antibody ON105 results in significant tumor regression in murine models of cancerAlejandro A Puchol Tarazona, Alexander Schinagl, Irina Mirkina, et al.
Molecular Cancer Therapeutics|July 4, 2024
Pretargeted Radioimmunotherapy with the Novel Anti-oxMIF/HSG Bispecific Antibody ON105 Results in Significant Tumor Regression in Murine Models of CancerAlejandro A Puchol Tarazona, Alexander Schinagl, Irina Mirkina, et al.
Molecular Cancer Therapeutics|April 17, 2023
Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer TherapeuticGregor Rossmueller, Irina Mirkina, Barbara Maurer, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Antioxidants & Redox Signaling|August 24, 2005
Link between macrophage migration inhibitory factor and cellular redox regulationMichael Thiele, Jürgen Bernhagen
Methods in Molecular Biology (Clifton, N.J.)|May 13, 2026
Detection of Oxidized Macrophage Migration Inhibitory Factor (oxMIF) in Biological Samples Using Enzyme-Linked Immunosorbent Assay (ELISA)Gregor Rossmueller, Michael Thiele
Current Hematology Reports|May 4, 2005
Diagnosis of polycythemia vera based on bone marrow pathologyJuergen Michael Thiele, Hans Michael Kvasnicka
Journal for Immunotherapy of Cancer|September 30, 2022
OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseasesMichael Thiele, Seamas C Donnelly, Robert A Mitchell
Antibodies (Basel, Switzerland)|December 27, 2024
Integrating In Silico and In Vitro Tools for Optimized Antibody Development-Design of Therapeutic Anti-oxMIF AntibodiesGregor Rossmueller, Irina Mirkina, Michael Thiele, et al.
Circulation|December 24, 2003
Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient miceAndreas Schober, Jürgen Bernhagen, Michael Thiele, et al.
FEBS Letters|March 11, 2005
Binding of JAB1/CSN5 to MIF is mediated by the MPN domain but is independent of the JAMM motifAnke Burger-Kentischer, Doris Finkelmeier, Michael Thiele, et al.
Molecular Cancer Therapeutics|June 4, 2024
Pretargeted radioimmunotherapy with the novel anti-oxMIF/HSG bispecific antibody ON105 results in significant tumor regression in murine models of cancerAlejandro A Puchol Tarazona, Alexander Schinagl, Irina Mirkina, et al.
Molecular Cancer Therapeutics|July 4, 2024
Pretargeted Radioimmunotherapy with the Novel Anti-oxMIF/HSG Bispecific Antibody ON105 Results in Significant Tumor Regression in Murine Models of CancerAlejandro A Puchol Tarazona, Alexander Schinagl, Irina Mirkina, et al.
Molecular Cancer Therapeutics|April 17, 2023
Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer TherapeuticGregor Rossmueller, Irina Mirkina, Barbara Maurer, et al.
Pageof 3